Jaguar Health (JAGX) received notice from the U.S. Food and Drug Administration’s Center for Veterinary Medicine of a $250,000 grant. Canalevia, under the name Canalevia-CA1, is currently conditionally approved for chemotherapy-induced diarrhea in dogs. The grant would support a confirmatory study required for full FDA approval of Canalevia for the treatment of CID in dogs. Acceptance of the award is dependent upon the company’s compliance with FDA terms and conditions. The company has not yet accepted the award.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAGX:
- Jaguar Animal Health Completes Private Placement of Preferred Stock
- Jaguar Animal Health Earnings Call: Growth Amid Challenges
- Jaguar Health to participate in 2025 Animal Health Summit
- Jaguar Health Announces Promising Trial Results
- Jaguar Health’s Napo to meet with FDA on pathways for croflemer in MVID